The only evidence based neuroprotective therapy for acute ischemic stroke: Thrombolysis

Best Practice and Research: Clinical Anaesthesiology

Volumn 24, Issue 4, 2010, Pages 563-571

  Köhrmann, Martin ^a   Schellinger, Peter D ^a   Schwab, Stefan ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Acute ischemic stroke; Interventional treatment; Thrombolysis

Indexed keywords

ALTEPLASE; DESMOTEPLASE; PLACEBO; SARUPLASE;

BLOOD CLOT LYSIS; BRAIN ISCHEMIA; CLINICAL TRIAL; FIBRINOLYTIC THERAPY; HUMAN; NEUROPROTECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REVIEW; THROMBUS;

BRAIN ISCHEMIA; CLINICAL TRIALS AS TOPIC; FIBRINOLYTIC AGENTS; HUMANS; NEUROPROTECTIVE AGENTS; PRACTICE GUIDELINES AS TOPIC; STROKE; THROMBOLYTIC THERAPY;

EID: 78649680303     PISSN: 15216896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bpa.2010.10.002     Document Type: Review

References (34)

1. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008 Cerebrovascular Diseases 25 5 2008 457 507
2. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group New England Journal of Medicine 333 24 1995 Dec 14 1581 1587
3. W. Hacke, M. Kaste, and C. Fieschi Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study Journal of the American Medical Association 274 1995 1017 1025
4. W. Hacke, M. Kaste, and C. Fieschi Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II) Lancet 352 1998 1245 1251
5. W.M. Clark, S. Wissman, and G.W. Albers Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase thrombolysis for acute noninterventional therapy in ischemic stroke Journal of the American Medical Association 282 21 1999 2019 2026
6. W.M. Clark, G.W. Albers, and K.P. Madden The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g): results of a double-blind, placebo-controlled, multicenter study. Thrombolytic therapy in acute ischemic stroke study investigators Stroke 31 4 2000 811 816
7. W. Hacke, E. Bluhmki, and T. Steiner Dichotomized efficacy end points and global end-point analysis applied to the ECASS intention-to-treat data set. Post hoc analysis of ECASS 1 Stroke 29 1998 2073 2075
8. W. Hacke, T. Brott, and L. Caplan Thrombolysis in acute ischemic stroke: controlled trials and clinical experience Neurology 53 7 1999 S3 S14
9. J.M. Wardlaw, G. del Zoppo, and T. Yamaguchi Thrombolysis for acute ischaemic stroke (Cochrane review) The Cochrane Library 2002
10. W. Hacke, G. Donnan, and C. Fieschi Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials Lancet 363 9411 2004 Mar 6 768 774
11. W. Hacke, M. Kaste, and E. Bluhmki Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke New England Journal of Medicine 359 13 2008 Sep 25 1317 1329
12. N. Wahlgren, N. Ahmed, and A. Davalos Thrombolysis with alteplase for acute ischaemic stroke in the safe implementation of thrombolysis in stroke-monitoring study (SITS-MOST): an observational study Lancet 369 9558 2007 Jan 27 275 282
13. N. Wahlgren, N. Ahmed, and A. Davalos Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study Lancet 372 9646 2008 Oct 11 1303 1309
14. C.S. Kidwell, J.R. Alger, and J.L. Saver Beyond mismatch: evolving paradigms in imaging the ischemic penumbra with multimodal magnetic resonance imaging Stroke 34 11 2003 Nov 2729 2735
15. J.A. Chalela, D.W. Kang, and M. Luby Early magnetic resonance imaging findings in patients receiving tissue plasminogen activator predict outcome: insights into the pathophysiology of acute stroke in the thrombolysis era Annals of Neurology 55 1 2004 Jan 105 112
16. G. Schlaug, B. Siewert, and A. Benfield Time course of the apparent diffusion coefficient (ADC) abnormality in human stroke Neurology 49 1 1997 113 119
17. S. Warach Tissue viability thresholds in acute stroke: the 4-factor model Stroke 32 11 2001 2460 2461
18. P.D. Schellinger, J.B. Fiebach, and W. Hacke Imaging-based decision making in thrombolytic therapy for ischemic stroke: present status Stroke 34 2 2003 Feb 575 583
19. L.L. Latour, D.W. Kang, and M.A. Ezzeddine Early blood-brain barrier disruption in human focal brain ischemia Annals of Neurology 56 4 2004 Oct 468 477
20. J. Fiehler, G.W. Albers, and J.M. Boulanger Bleeding risk analysis in stroke imaging before thrombolysis (BRASIL): pooled analysis of T2 (*)-weighted magnetic resonance imaging data from 570 patients Stroke 38 10 2007 Oct 2738 2744
21. G.W. Albers, V. Thijs, and L. Wechsler Results of the diffusion-weighted imaging evaluation for understanding stroke evolution (DEFUSE) study Stroke 37 2 2006 635 636
22. S.M. Davis, G.A. Donnan, and M.W. Parsons Effects of alteplase beyond 3 h after stroke in the echoplanar imaging thrombolytic evaluation trial (EPITHET): a placebo-controlled randomised trial Lancet Neurology 7 4 2008 Apr 299 309
23. G. Thomalla, C. Schwark, and J. Sobesky Outcome and symptomatic bleeding complications of intravenous thrombolysis within 6 hours in mri-selected stroke patients: comparison of a German multicenter study with the pooled data of ATLANTIS, ECASS, and NINDS tPA trials Stroke 37 3 2006 Mar 852 858
24. Köhrmann M, Jüttler E, Schwark C, Fiebach JB, Huttner HB, Siebert S, et al. MRI-based thrombolysis within and beyond the 3 hour time window is as safe and effective as standard CT-based treatment. Lancet Neurology 2006 Aug; 5(8):661 - 7.
25. P.D. Schellinger, G. Thomalla, and J. Fiehler MRI-based and CT-based thrombolytic therapy in acute stroke within and beyond established time windows: an analysis of 1210 patients Stroke 38 10 2007 Oct 2640 2645
26. W. Hacke, G. Albers, and Y. Al-Rawi The desmoteplase in acute ischemic stroke trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase Stroke 36 1 2005 Jan 66 73
27. A.J. Furlan, D. Eyding, and G.W. Albers Dose escalation of desmoteplase for acute ischemic stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset Stroke 37 5 2006 May 1227 1231
28. W. Hacke, A.J. Furlan, and Y. Al-Rawi Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study Lancet Neurology 8 2 2009 Feb 141 150
29. G.J. del Zoppo, R.T. Higashida, and A.J. Furlan PROACT: a phase ii randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke Stroke 29 1998 4 11
30. A. Furlan, R. Higashida, and L. Wechsler Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in acute cerebral thromboembolism Journal of the American Medical Association 282 21 1999 2003 2011
31. The IMS Study Investigators Combined intravenous and intra-arterial recanalization for acute ischemic stroke: the Interventional Management of Stroke Study Stroke 35 4 2004 Apr 904 911
32. The interventional management of stroke (IMS) II study Stroke 38 7 2007 Jul 2127 2135
33. The penumbra pivotal stroke trial: safety and effectiveness of a new generation of mechanical devices for clot removal in intracranial large vessel occlusive disease Stroke 40 8 2009 Aug 2761 2768
34. P. Khatri, M.D. Hill, and Y.Y. Palesch Methodology of the interventional management of stroke III trial International Journal of Stroke 3 2 2008 May 130 137 (Pubitemid 351566847)